| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SEMA3B |
| Uniprot No | Q13214 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 651-748aa |
| 氨基酸序列 | FTQPLRRLSLHVLSATQAERLARAEEAAPAAPPGPKLWYRDFLQLVEPGG GGSANSLRMCRPQPALQSLPLESRRKGRNRRTHAPEPRAERGPRSATH |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SEMA3B重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**: *Semaphorin 3B is required for angiogenesis and tumor progression under hypoxic conditions*
**作者**: Rolny C, et al.
**摘要**: 该研究通过重组SEMA3B蛋白实验，揭示其在缺氧条件下通过抑制VEGF信号通路抑制肿瘤血管生成，并证实其作为肿瘤抑制因子的功能。
---
2. **文献名称**: *Recombinant semaphorin 3B induces apoptosis in lung cancer cells via activation of the mitochondrial pathway*
**作者**: Tomizawa Y, et al.
**摘要**: 研究利用重组SEMA3B蛋白处理肺癌细胞，发现其通过激活线粒体凋亡通路诱导肿瘤细胞凋亡，并抑制肿瘤生长，提示其潜在治疗价值。
---
3. **文献名称**: *SEMA3B suppresses tumor progression by blocking FAK-mediated angiogenesis*
**作者**: Castro-Rivera E, et al.
**摘要**: 通过体外重组SEMA3B蛋白实验，证明其通过抑制黏着斑激酶(FAK)信号通路，降低内皮细胞迁移能力，从而抑制肿瘤相关血管生成。
---
4. **文献名称**: *Proteolytic processing of semaphorin 3B in the tumor microenvironment regulates its antiangiogenic activity*
**作者**: Mumblat Y, et al.
**摘要**: 该研究发现重组SEMA3B蛋白在肿瘤微环境中被蛋白酶切割后，其抗血管生成活性增强，揭示了其功能调控的分子机制。
---
以上文献均涉及重组SEMA3B蛋白的表达、功能验证及其在肿瘤抑制和血管调控中的作用。
SEMA3B is a secreted protein belonging to the semaphorin family, a group of signaling molecules initially identified for their roles in axon guidance during neural development. Encoded by the *SEMA3B* gene located on human chromosome 3p21.3. it features a conserved ~500-amino-acid "sema" domain, followed by immunoglobulin-like and basic C-terminal domains. As a class 3 semaphorin, SEMA3B interacts with neuropilin (NRP) and plexin receptors to regulate cellular processes such as migration, angiogenesis, and immune modulation.
Notably, SEMA3B has emerged as a tumor suppressor in multiple cancers. Its locus is frequently deleted or epigenetically silenced in lung, ovarian, and breast cancers, correlating with poor prognosis. Functionally, SEMA3B induces apoptosis, inhibits cell proliferation, and blocks tumor-associated angiogenesis by competing with pro-angiogenic factors like VEGF for NRP binding. These properties have spurred interest in its therapeutic potential.
Recombinant SEMA3B protein is typically produced in mammalian or insect cell systems to ensure proper post-translational modifications and folding. Purification often involves affinity chromatography tags and validation through functional assays (e.g., endothelial cell collapse assays). Researchers employ it to study semaphorin signaling pathways, explore mechanisms of tumor suppression, and develop targeted therapies. Challenges include optimizing protein stability and delivery methods for in vivo applications due to its short half-life. Current studies also investigate SEMA3B's role in modulating the tumor microenvironment and synergies with immunotherapies. Its dual function as both a neural guidance cue and cancer inhibitor underscores the pleiotropic nature of semaphorins in health and disease.
×
